Hemovent has raised a $6 million Series A financing to support the development of what it expects will be the world's smallest and first self-contained and fully portable Extra Corporeal Membrane Oxygenation (ECMO) system to support or replace heart and lung function.
Startup Xenios has zeroed in its platform of minimally invasive products to treat patients with heart and lung problems. Its latest addition is i-cor, a synchronized cardiac assist system that just received a CE mark for marketing in Europe. This makes it the first heartbeat-synchronized cardiac assist device for cardiogenic shock and high-risk interventions.
Reseachers at Carnegie Mellon have hacked a sub-$3K consumer 3-D printer to create biological-material models of embryonic hearts, arteries, bones and even human brain tissue. The hope is that this work could lead to tissue creation that is adequate to repair soft tissue in the human body. The work is being done using open-source software, enabling other researchers to more easily replicate it.
Researchers published last winter on the creation of a biodegradable adhesive patch to repair holes in the heart. Now they have developed a UV-light-based catheter that can deliver the patch, thereby obviating the need for open heart surgery.
Following up on some promising rodent studies, a team of investigators at UC San Francisco has helped substantiate that elevated levels of two proteins are linked with healthier hearts--an insight that will likely inspire more work into new cardiology therapies.
3-D printer Materialise and Beijing-based cardiovascular specialist Fuwai Hospital have partnered to open a multidisciplinary 3-D printing center for use in clinical planning. Medical uses are a large and fast growing segment for Materialise, which has done several high-profile deals targeting the industry.
A group of bioengineers at UC Berkeley has been hard at work hatching a new "heart-on-a-chip" technology that aims to offer researchers a better, less expensive way to develop new drugs.
Swiss med tech Xeltis has raised €27 million ($34 million) in an oversubscribed Series B round. The financing will be used mostly to help get its first product to market, a biodegradable pulmonary valve intended for patients with severe congenital malformations of the heart, an orphan pediatric indication.
Researchers in Italy have found microRNAs (miRNAs), tiny fragments of genetic material, that regenerate tissue in mouse hearts.
Doctors use a 50-year-old invasive heart imaging test known as a left ventriculography or left ventriculogram much too often, a Stanford University School of Medicine study concludes.